COLORADO SPRINGS, Colo., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.
Cannabis Science President and CEO Dr. Robert Melamede, PhD., commented, "Obviously, this study gives further support to our plans to work within the multi-billion dollar market of chronic neuropathic pain. As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?"
McGill's study is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes. Participants were divided into four groups and randomly assigned marijuana containing four levels of tetrahydrocannabinol (THC), the active ingredient: at 9.4 per cent, 6.0 per cent, 2.5 per cent, and zero THC. The study was led by anesthesiologist Mark Ware, director of clinical research at Montreal's Alan Edwards Pain Management Unit at the McGill University Health Centre. It was published in the Canadian Medical Association Journal. Please see: http://www.cmaj.ca/cgi/rapidpdf/cmaj.091414v1?ijkey=44cf2a4e01bb03581946f0ab6b7217d7a6e78f0b
Richard Cowan, Cannabis Science CFO, added, "This study demonstrates the importance of our licensing agreement with the RockBrook dispensary of Denver which we announced on August 18th, which gives us the immediate ability to test our formulations with humans to help determine exactly what doses and strains work best for patients as we prepare to enter clinical trials." See http://cannabisscience.com/news-a-media/press-releases/200-cbis-signs-first-licensing-agreement-with-rockbrook.html
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc. Dr. Robert J. Melamede, President & CEO 1-888-889-0888 Investor Relations Mark J. Friedman 1-877-431-CBIS (2247) email@example.com www.cannabisscience.com